Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin for Vasomotor Symptoms and Cardiovascular Control
NCT02202707Withdrawn
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gabapentin in vasomotor symptoms, sponsored by Beth Israel Deaconess Medical Center. Primary endpoints: Alterations in cardiovagal tone with treatment of vasomotor symptoms in women at 5 weeks and Alterations in sympathetic efferent outflow with treatment of vasomotor symptoms at 5 weeks. Planned start May 2014; status: withdrawn.
02
Drugs
gabapentin
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT02202707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202707.